The FDA has denied Stealth BioTherapeutics’ request to reconsider its complete response letter, leaving the fate of the biotech and its investigational treatment for an ultrarare genetic disease ...

Genomics is stepping up to buy Scale Biosciences and its single-cell profiling solutions, with plans to implement them within ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, ...

After emerging from stealth earlier this year, Apreo Health has raised $130 million to breathe new life into the development ...

When you think of biotech hubs, the first image that comes to mind may be the sleek waterfront offices of Boston Seaport or ...

Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into 2028. | Bicycle Therapeutics is ...

Longevity company Altos Labs has secured a new clinical leader from the eye of the storm. Former Tornado Therapeutics ...

When Tiba Biotech was included in the cancelation of $500 million worth grants funding mRNA vaccine development, the company ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

A group of more than a dozen investors have together purchased a majority stake in HistoSonics, following reports earlier ...

In its own statement, Edwards said it disagrees with the FTC’s belief that the acquisition will limit access to a new therapy ...

An impressive array of Big Pharma backers have lined up to ensure Strand Therapeutics has the funding needed to take its mRNA ...